首頁 > 市場調查報告書 > 製藥

醫藥品法規環境

市場調查報告書

商品編碼

1186742

藥物警戒軟件市場：現狀分析與預測（2022-2028 年）

Pharmacovigilance Software Market: Current Analysis and Forecast (2022-2028)

出版日期: 2022年12月01日 | 出版商:

UnivDatos Market Insights Pvt Ltd | 英文 149 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

在預測期內，全球藥物警戒軟件市場規模預計將以 8% 左右的增長率增長。藥物警戒有助於藥物不良反應的早期發現和自發報告，是監測和評估藥物不良反應的過程，是有效藥物監管體系、公共衛生計劃和臨床研究計劃的重要組成部分。為滿足客戶要求，藥物警戒軟件供應商提供了單獨且完整的解決方案。癌症患者的增加正在推動報告系統和藥物警戒新技術以及研發和臨床研究項目的變革，從而推動市場的增長。

本報告審視了全球藥物警戒軟件市場，並按功能、交付方式、最終用戶、地區和進入市場的公司概況提供了市場概況以及趨勢。

內容

第一章市場介紹

第2章研究方法或假設

第三章市場總結

第 4 章執行摘要

第 5 章 COVID-19 對藥物警戒軟件的影響

第 6 章藥物警戒軟件市場收入，2020-2028

第 7 章功能市場洞察

不良事件報告軟件
藥物安全審計軟件
問題跟蹤軟件
完全集成的軟件

第 8 章交付模式的市場洞察

現場交付
按需/基於雲的 (SaaS) 交付

第 9 章最終用戶的市場洞察

製藥和生物技術公司
首席風險官
業務流程外包公司
其他

第 10 章按地區劃分的市場洞察

北美
歐洲
亞太地區
其他地區

第 11 章藥物警戒軟件市場動態

市場驅動力
市場挑戰
影響分析

第 12 章藥物警戒軟件的市場機會

第 13 章藥物警戒軟件市場趨勢

第14章需求側與供給側分析

第 15 章價值鏈分析

第16章價格分析

第 17 章戰略洞察

第 18 章衝突場景

第十九章公司概況

IQVIA Inc.
Labcorp Drug Development
Parexel International Corporation
Accenture
Cognizant
Clario
Thermo Fisher Scientific Inc.
ICON plc
Quanticate
AB Cube S.A.S.

第20章免責事項

簡介目錄

Product Code: UMME211560

The global pharmacovigilance software market is expected to grow at a significant rate of around 8% during the forecast period. Pharmacovigilance is useful in the early detection and spontaneous reporting of adverse drug reactions, and it is the process of monitoring and evaluating adverse drug reactions and it is a key component of effective drug regulation systems, public health programs and clinical research programs. To meet the requirements of customers, vendors of pharmacovigilance software offer individualized and complete solutions. These vendors are additionally providing end-to-end solutions, for example, electronic information catch, artificial intelligence, and interoperability, among others to enhance their offerings. In addition, stakeholders in the industry are moving toward the use of modern technology to help them with their pharmacovigilance tasks because of the combined pressures of volume, cost, and the increased demand for analytics.

Changing reporting systems and emerging technology in pharmacovigilance and rising cancer cases boosting the R&D and clinical research programs are driving the market growth. For instance, according to the data published by the American Cancer Society (ACS), in January 2020, around 1.8 million new cancer cases were diagnosed and 606,520 cancer deaths in the United States.

IQVIA Inc., Labcorp Drug Development, Parexel International Corporation, Accenture, Cognizant, Clario, Thermo Fisher Scientific Inc., ICON plc, Quanticate, and AB Cube S.A.S. are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report:

"Amongst functionality, adverse event reporting software category to witness robust CAGR during the forecast period"

Based on functionality, the market is segmented into adverse event reporting software, drug safety audits software, issue tracking software, and fully integrated software. Amongst, the adverse event reporting software category is to witness robust CAGR during the forecast period owing to the rising demand for safe medicines and drugs around the world on account of the increasing incidences of adverse drug reactions (ADRs) is contributing to market growth. Apart from this, due to the rapid digitization of clinical trials, there's a rise in the adoption of pharmacovigilance and medicine safety software to ensure the implementation of new methods also drives the market growth during the forecast period.

"Amongst end-users, the pharmaceutical and biotechnology companies to hold a significant share in the market in 2020"

On the basis of end-users, the market is categorized into pharmaceutical and biotechnology companies, contract research organizations, business process outsourcing firms, and others. Among these, the pharmaceutical and biotechnology companies to hold a significant share of the market in 2020. This is mainly due to the extensive research and development efforts by several pharmaceutical companies and these companies are also launching new products which will also contribute to the growth of the market. For instance, Dialog Solutions launched the next generation of pharmacovigilance literature monitoring in 2021.

In addition, multiple adverse events, or adverse reactions force research organizations to turn to pharmacovigilance services for clinical trials, raising the demand for the growth of the market during the forecast period.

"North America to hold a significant share in the market"

For a better understanding of the market adoption of the pharmacovigilance software industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. This is mainly due to increasing Initiatives undertaken by the governments, investment in the research & development process and adoption of solutions, and the availability of major key market players in the region propelling the growth rate of the market growth during the forecast period. For instance, in 2021, the Open FDA initiative undertaken by the US government provides access to its database through open search-based programs for application developers and scientists.

Reasons to buy this report:

The study includes market sizing and forecasting analysis validated by authenticated key industry experts.

The report presents a quick review of overall industry performance at one glance.

The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.

Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.

The study comprehensively covers the market across different segments.

Deep dive regional level analysis of the industry.

Customization Options:

The global pharmacovigilance software market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

1 MARKET INTRODUCTION

1.1. Market Definitions
1.2. Main Objective
1.3. Stakeholders
1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

2.1. Research Process of the Pharmacovigilance Software Market
2.2. Research Methodology of the Pharmacovigilance Software Market
2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE PHARMACOVIGILANCE SOFTWARE MARKET

6 PHARMACOVIGILANCE SOFTWARE MARKET REVENUE, 2020-2028F

7 MARKET INSIGHTS BY FUNCTIONALITY

7.1. Adverse Event Reporting Software
7.2. Drug Safety Audits Software
7.3. Issue Tracking Software
7.4. Fully Integrated Software

8 MARKET INSIGHTS BY MODE OF DELIVERY

8.1. On-Premises Delivery
8.2. On-Demand/ Cloud-Based (SaaS) Delivery

9 MARKET INSIGHTS BY END-USERS

9.1. Pharmaceutical and Biotechnology Companies
9.2. Contract Research Organizations
9.3. Business Process Outsourcing Firms
9.4. Others

10 MARKET INSIGHTS BY REGION

10.1. North America
- 10.1.1. U.S.
- 10.1.2. Canada
- 10.1.3. Rest of North America
10.2. Europe
- 10.2.1. Germany
- 10.2.2. U.K.
- 10.2.3. France
- 10.2.4. Italy
- 10.2.5. Spain
- 10.2.6. Rest of Europe
10.3. Asia-Pacific
- 10.3.1. China
- 10.3.2. Japan
- 10.3.3. India
- 10.3.4. Rest of Asia-Pacific
10.4. Rest of World